Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

CVS Caremark, Express Scripts and OptumRx and have fended off federal legislation targeting pharmacy benefit managers, but ...

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS Caremark, the country's largest Pharmacy Benefit Manager (PBM) has decided that Wegovy ® (semaglutide ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.